• Company
• Patent dispute for Soliris faces 2nd trial/original company
• by Kim, Jin-Gu Apr 23, 2023 08:22pm

• Company
• Pfizer Launches 'Pfizer Pro', a Customized Digital Platform
• by Eo, Yun-Ho Apr 23, 2023 07:48pm

• Policy
• CPAC 'Reducing PMS cases for Zerbaxa deemed valid'
• by Lee, Hye-Kyung Apr 21, 2023 05:56am

• Company
• Piqray to soon be deliberated by CDDC for reimb
• by Eo, Yun-Ho Apr 21, 2023 05:55am

• Product
• Olumiant set the first milestone for circular hair loss
• by Hwang, byoung-woo Apr 20, 2023 05:58am

• Company
• Expansion of reimbursement for DM drugs
• by Moon, sung-ho Apr 20, 2023 05:58am

• Policy
• SGLT2 Domestic new drug/combined drug market
• by Lee, Tak-Sun Apr 20, 2023 05:58am

• Company
• New heart failure drug Verquvo lands at general hospitals
• by Eo, Yun-Ho Apr 20, 2023 05:58am

• Policy
• NA presses for Targrisso’s reimb in the first line
• by Lee, Jeong-Hwan Apr 20, 2023 05:58am

• Policy
• Enhertu, re-discussing with supplementary materials
• by Lee, Tak-Sun Apr 19, 2023 05:51am